MRNS Marinus Pharmaceuticals Inc

Price (delayed)

$18.5

Market cap

$677.72M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.4

Enterprise value

$554.25M

Highlights
The EPS has grown by 44% YoY and by 14% from the previous quarter
The equity has surged by 168% year-on-year but it has declined by 16% since the previous quarter
The company's quick ratio fell by 41% QoQ but it rose by 3.9% YoY
The net income has declined by 26% year-on-year and by 13% since the previous quarter

Key stats

What are the main financial stats of MRNS
Market
Shares outstanding
36.63M
Market cap
$677.72M
Enterprise value
$554.25M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.87
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$75.94M
EBITDA
-$75.33M
Free cash flow
-$63.48M
Per share
EPS
-$2.4
Free cash flow per share
-$1.73
Book value per share
$3.15
Revenue per share
$0
TBVPS
$3.66
Balance sheet
Total assets
$133.86M
Total liabilities
$18.53M
Debt
$0
Equity
$115.33M
Working capital
$113.68M
Liquidity
Debt to equity
0
Current ratio
8.05
Quick ratio
7.82
Net debt/EBITDA
1.64
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-61.1%
Return on equity
-68.9%
Return on invested capital
-9,347%
Return on capital employed
-64.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MRNS stock price

How has the Marinus Pharmaceuticals stock price performed over time
Intraday
1.98%
1 week
-1.02%
1 month
26.28%
1 year
73.22%
YTD
51.64%
QTD
19.51%

Financial performance

How have Marinus Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$79.82M
Net income
-$75.94M
Gross margin
N/A
Net margin
N/A
The company's operating income fell by 31% YoY and by 15% QoQ
The net income has declined by 26% year-on-year and by 13% since the previous quarter

Growth

What is Marinus Pharmaceuticals's growth rate over time

Valuation

What is Marinus Pharmaceuticals stock price valuation
P/E
N/A
P/B
5.87
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 44% YoY and by 14% from the previous quarter
The equity has surged by 168% year-on-year but it has declined by 16% since the previous quarter
The price to book (P/B) is 73% higher than the 5-year quarterly average of 3.4 and 63% higher than the last 4 quarters average of 3.6

Efficiency

How efficient is Marinus Pharmaceuticals business performance
The ROIC has dropped by 62% year-on-year
The ROE has soared by 54% YoY and by 17% from the previous quarter
The company's return on assets rose by 36% YoY and by 10% QoQ

Dividends

What is MRNS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MRNS.

Financial health

How did Marinus Pharmaceuticals financials performed over time
The total assets has soared by 58% YoY but it has contracted by 11% from the previous quarter
Marinus Pharmaceuticals's current ratio has decreased by 41% from the previous quarter but it has increased by 3.9% YoY
MRNS's debt is 100% lower than its equity
The equity has surged by 168% year-on-year but it has declined by 16% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.